To analyze the clinical characteristics and prognosis of multiple myeloma patients resisting to VRD (Bortezomib, Lenalidomide, Dexamethasone)

JIA Jing, CHEN Wenming, GENG Chuanying, YANG Guangzhong, ZHOU Huixing, JIAN Yuan, LIU Nian, ZHANG Zhiyao

PDF(808 KB)
Tumor website：www.tumorsci.org E-mail Alert
PDF(808 KB)
Tumor ›› 2023, Vol. 43 ›› Issue (09) : 701-709. DOI: 10.3781/j.issn.1000-7431.2023.2303-0134
Original Research

To analyze the clinical characteristics and prognosis of multiple myeloma patients resisting to VRD (Bortezomib, Lenalidomide, Dexamethasone)

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 43(09): 701-709 https://doi.org/10.3781/j.issn.1000-7431.2023.2303-0134

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(808 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Tumor, All Rights Reserved.
E-mail: tumor@tumorsci.org
Powered by Beijing Magtech Co., Ltd.

/

〈 〉